GET DAILY SIGNALSBMY +19% YTD: Why Bristol Myers Squibb (BMY) Holds an Edge Over GSK (GSK)
Key Takeaways
- BMY has delivered stronger relative momentum in recent months, with shares advancing roughly 19% year to date and outperforming the broader healthcare industry and the S&P 500.
- GSK has faced a sharper near-term pullback, with shares falling as much as 5.4% in a single session after its latest quarterly update as weakening vaccine sales overshadowed an earnings beat.
- Both companies are navigating patent-related headwinds: BMY's Eliquis faces loss of exclusivity in Europe, while GSK's blockbuster HIV medicine dolutegravir confronts expiries beginning around 2028.
- Tickeron AI Verdict: BMY — based on stronger trend consistency, more favorable relative performance, and a higher dividend yield, the AI-driven analysis currently leans toward BMY over GSK.
- For more detail, explore BMY Major News and BMY Today's Price Move, as well as GSK Major News and GSK Today's Price Move.
- To see how AI trading systems are positioning across these and other tickers, visit Trending AI Robots.
Introduction
Bristol Myers Squibb (BMY) and GSK plc (GSK) rank among the world’s largest pharmaceutical companies, though they hold different places in the global healthcare sector. Both represent value-oriented holdings with attractive dividend yields, and both are working through the shift from older blockbuster products to newer growth areas. This comparison matters for income investors focused on dividend sustainability as well as for traders assessing relative strength and positioning. Looking at recent results, catalysts, and risks together helps clarify which of these large-cap drugmakers may present the more attractive risk-reward setup at the moment.
BMY Overview and Recent Performance
Bristol Myers Squibb is a U.S.-based biopharmaceutical company focused on oncology, hematology, cardiovascular, and immunology. In its latest quarter, the firm reported revenue of about $13.07 billion, an increase of roughly 7% year over year that topped consensus estimates, while adjusted EPS came in below the prior-year level yet still beat expectations. The Growth Portfolio drove much of the improvement, rising about 12% year over year thanks to products including Reblozyl, Breyanzi, Camzyos, and Opdualag. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market action has been constructive for BMY, which has risen roughly 19% year to date and outperformed both its industry peers and the broader market. Positive sentiment has been supported by solid top-line results and an active pipeline, though the picture is tempered by an expected reduction in Eliquis revenue after loss of exclusivity in Europe and ongoing generic pressure on older products such as Revlimid. The dividend yield near 4% continues to appeal to income-focused investors.
GSK Overview and Recent Performance
GSK plc is a UK-based global biopharmaceutical company active in vaccines, specialty medicines, and general medicines, with key franchises in HIV, respiratory, oncology, and infectious disease. In its most recent quarter, GSK posted sales of roughly £8.89 billion, up about 5% at constant currency, while core operating profit also grew about 5% and core EPS exceeded analyst forecasts. Specialty medicines led the way, rising approximately 15%, and oncology climbed more than 20%.
Despite the earnings beat, recent trading has been less favorable for GSK. The stock dropped sharply after the update, with shares declining as much as 5.4%—the largest intraday move in months—as investors focused on an approximately 2% decline in vaccine sales and softer demand for Shingrix and Arexvy. Under new CEO Luke Miels, GSK is implementing a £1.9 billion cost-savings program and rebuilding its pipeline ahead of HIV patent expiries expected between 2028 and 2030. Its dividend yield near 3.6% is respectable but trails BMY.
Head-to-Head Comparison
Although both are large-cap pharmaceutical companies, their business models differ in meaningful respects. BMY generates nearly 70% of sales from the United States and is heavily weighted toward oncology and cardiovascular treatments, with significant exposure to Eliquis and its growth portfolio. GSK is more geographically diversified, maintains a sizable vaccines business, and holds a leading position in HIV through its ViiV Healthcare joint venture.
On growth drivers, BMY is seeing double-digit gains in newer medicines and maintains a robust late-stage pipeline, although near-term updates have produced mixed reactions. GSK is benefiting from a 15% increase in specialty medicines and strong oncology momentum, yet its vaccine segment remains a clear near-term headwind. Both face patent cliffs—BMY more immediately with Eliquis in Europe and GSK later in the decade with dolutegravir. In terms of sentiment, BMY has shown more consistent positive momentum, while GSK has experienced a sharper, sentiment-driven selloff linked to its vaccine franchise.
Tickeron AI Verdict
Based on the observable factors, Tickeron’s AI analysis currently favors BMY over GSK. BMY has demonstrated more consistent trend strength and superior relative performance in recent months, supported by double-digit growth in its newer product portfolio and a higher dividend yield that improves total-return potential. In contrast, GSK has shown greater short-term volatility, with weakening vaccine demand serving as a near-term overhang despite underlying strength in specialty medicines. While both names carry patent-related risks, the combination of momentum, stability, and income currently tilts the AI-driven view toward BMY, in probabilistic rather than absolute terms.
Exploring AI Trading Strategies
In my research, I often turn to Tickeron’s AI Trading Bots to see how automated systems are positioned across names like these. The platform provides a range of bots with varying risk profiles, timeframes, and performance statistics that can add a systematic layer to fundamental work. AI Trading Bots
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GSK in -1.82% downward trend, falling for three consecutive days on November 11, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GSK declined for three days, in 159 of 288 cases, the price declined further within the following month. The odds of a continued downward trend are 55%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
GSK broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on GSK as a result. In 50 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for GSK just turned positive on November 04, 2026. Looking at past instances where GSK's MACD turned positive, the stock continued to rise in 32 of 46 cases over the following month. The odds of a continued upward trend are 70%.
GSK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GSK crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +3.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in 202 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 145 of 258 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. GSK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.715) is normal, around the industry mean (-1.421). P/E Ratio (20.988) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (6.052) is also within normal values, averaging (5.738). Dividend Yield (0.035) settles around the average of (0.038) among similar stocks. P/S Ratio (2.294) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and other pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement